UCB: Focused on Expanding Patient Population and Developing Pipeline Amid Generic Pressure

UCB remains focused on expanding its addressable patient population and developing its pipeline as the company continues to face generic competition. UCB’s epilepsy drug Briviact received approval in Japan for the treatment of focal onset seizures. This is the fourth approval of Briviact in the Asia-Pacific region, which reinforces UCB’s commitment to expanding treatment to people with epilepsy across the globe. We forecast Briviact will achieve peak sales of roughly EUR 700 million in 2026 and then it will face declining sales due to its loss of patent exclusivity in the United States and European Union in 2026.